menu
    • menu

    Company profile for Estrella Biopharma

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Estrella Biopharma is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. It focuses to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer. The company is based in Emeryville, California.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Estrella BiopharmaUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    5858 Horton Street Suite 170 Emeryville, California, 94608
    Telephone
    Telephone
    (510) 318-9098
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.estrellabio.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Estrella Immunopharma Finishes Second Dose Cohort In STARLIGHT-1
    Estrella Immunopharma Finishes Second Dose Cohort In STARLIGHT-1

    03 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251030827975/en/Estrella-Immunopharma-Completes-Second-Dose-Cohort-in-STARLIGHT-1-Trial-of-EB103-with-Complete-Responses-in-All-Evaluable-Patients

    BUSINESSWIRE
    03 Nov 2025
    Share Share
    Estrella Immunopharma Restores Nasdaq Listing Compliance
    Estrella Immunopharma Restores Nasdaq Listing Compliance

    06 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251006214562/en/Estrella-Immunopharma-Regains-Compliance-with-Nasdaq-Listing-Requirements

    BUSINESSWIRE
    06 Oct 2025
    Share Share
    Estrella Adds Trial Site for Ph I/II in Non-Hodgkin's Lymphoma
    Estrella Adds Trial Site for Ph I/II in Non-Hodgkin's Lymphoma

    05 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250605259623/en/Estrella-Immunopharma-Announces-Activation-of-Additional-Site-for-Phase-III-STARLIGHT-1-Trial-in-B-cell-Non-Hodgkins-Lymphoma

    BUSINESSWIRE
    05 Jun 2025
    Share Share
    Estrella Immunopharma Announces $3.35M Private Placement
    Estrella Immunopharma Announces $3.35M Private Placement

    03 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250603900199/en/Estrella-Immunopharma-Announces-Approximately-%243.35-Million-Private-Placement-Equity-Financing

    BUSINESSWIRE
    03 Jun 2025
    Share Share
    Estrella Immunopharma Starts Second Cohort in EB103 Trial
    Estrella Immunopharma Starts Second Cohort in EB103 Trial

    29 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250529919302/en/Estrella-Immunopharma-Initiates-Second-Cohort-and-Doses-First-Patient-in-STARLIGHT-1-Trial-of-EB103-in-Advanced-B-Cell-Non-Hodgkins-Lymphomas

    BUSINESSWIRE
    29 May 2025
    Share Share
    Estrella Gets Buy Rating, $14 Target From CB Capital
    Estrella Gets Buy Rating, $14 Target From CB Capital

    05 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250305134461/en

    BUSINESSWIRE
    05 Mar 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search